middle.news
FDA Opens Regulatory Pathway for Argent BioPharma’s CannEpil Veterinary Program
9:50am on Wednesday 26th of August, 2026 AEST
•
Pharmaceuticals
Read Story
FDA Opens Regulatory Pathway for Argent BioPharma’s CannEpil Veterinary Program
9:50am on Wednesday 26th of August, 2026 AEST
Key Points
FDA-CVM establishes INAD File No. 14145 for CannEpil veterinary use
Initial focus on cancer-related pain management in canine oncology
Development led by Endovia Health Sciences and Lupvindol Biosciences
Argent retains IP ownership, manufacturing role, and 10% royalty
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argent Biopharma (ASX:RGT)
OPEN ARTICLE